APA (7th ed.) Citation

Singer, M., Khanani, A. M., Wolf, A., Flores, R., Chhablani, J., B, G., . . . Querques, G. (2022). Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials. Ophthalmologica, 245(4), 315. https://doi.org/10.1159/000524245

Chicago Style (17th ed.) Citation

Singer, Michael, et al. "Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A Post Hoc Evaluation of Data from the HAWK and HARRIER Trials." Ophthalmologica 245, no. 4 (2022): 315. https://doi.org/10.1159/000524245.

MLA (9th ed.) Citation

Singer, Michael, et al. "Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A Post Hoc Evaluation of Data from the HAWK and HARRIER Trials." Ophthalmologica, vol. 245, no. 4, 2022, p. 315, https://doi.org/10.1159/000524245.